A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO). (June 2014)

• Record Type: Journal Article
• Authors: Taylor, Matthew; Serbetci, Elçin; Ferreira, Alberto; Gairy, Kerry; Lewis, Lily; Blouin, Julie; Mitchell, Paul
• Is Part Of: Journal of medical economics. Volume 17:Number 6(2014)
• Page Start: 423
• Page End: 434
• Publication Date: 2014-06
• Subjects: Medical care -- Cost control -- Periodicals; Medical economics -- Periodicals; 362.10941
• DOI: 10.3111/13696998.2014.909435
• Languages: English
• ISSNs: 1369-6998

Abstract

<abstract> <title>Abstract</title> <sec id="ss1"> <title>Objective:</title> <p>This study compares the cost-effectiveness of intravitreal ranibizumab vs observation and/or laser photocoagulation for treatment of macular edema secondary to retinal vein occlusion in a UK-based model.</p> </sec> <sec id="ss2"> <title>Methods:</title> <p>A Markov model was constructed using transition probabilities and frequency of adverse events derived using data from the BRAVO, CRUISE, and HORIZON trials. Outcomes associated with treatments and health states were combined to predict overall health costs and outcomes for cohorts treated with each option.</p> </sec> <sec id="ss3"> <title>Results:</title> <p>In branch retinal vein occlusion, ranibizumab produced a gain of 0.518 quality-adjusted life years at an incremental cost of £8141, compared with laser photocoagulation. The incremental cost-effectiveness ratio was £15, 710 per quality-adjusted life year, and the incremental cost per month free from blindness was £658. In central retinal vein occlusion, ranibizumab produced a gain of 0.539 quality-adjusted life years at an incremental cost of £9216, compared with observation only. The incremental cost-effectiveness ratio was £17, 103, and the incremental cost per month free from blindness was £423.</p> </sec> <sec id="ss4"> <title>Conclusions:</title> <p>These incremental cost-effectiveness ratios are below the £20, 000–30, 000 range typically accepted as a threshold for cost-effectiveness. This suggests that ranibizumab may be regarded as a cost-effective therapy for patients with macular edema secondary to retinal vein occlusion, relative to grid laser photocoagulation (for BRVO) and observation (for CRVO). Limitations include sparse data for utilities associated with the severity of visual impairment in the WSE in patients with RVO. A lack of direct comparative evidence between ranibizumab and the dexamethasone intravitreal implant for the treatment of BRVO and CRVO and the infeasibility of an indirect comparison due to significant heterogeneity in trial designs prevented the inclusion of this treatment as a comparator in the Markov model.</p> </sec> </abstract>